Respiratory problems in neurologic movement disorders

Parkinsonism and Related Disorders

Volumn 16, Issue 10, 2010, Pages 628-638

  Mehanna, Raja ^a   Jankovic, Joseph ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Movement disorders; Myoclonus; Parkinson; Respiratory

Indexed keywords

ACETAZOLAMIDE; APOMORPHINE; BACLOFEN; BENZODIAZEPINE; BOTULINUM TOXIN A; BROMOCRIPTINE; CARBAMAZEPINE; CHLORDIAZEPOXIDE; CLONAZEPAM; CLONIDINE; ETIRACETAM; FLUPHENAZINE; GABAPENTIN; GLYCOPYRRONIUM BROMIDE; HALOPERIDOL; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; PERGOLIDE; PHENYTOIN; PIMOZIDE; PRAMIPEXOLE; RISPERIDONE; ROPINIROLE; ROTIGOTINE; TETRABENAZINE; TOPIRAMATE; UNINDEXED DRUG; VALPROIC ACID; ZONISAMIDE;

ASPIRATION PNEUMONIA; CHOREA; DRUG WITHDRAWAL; DYSTONIA; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUNTINGTON CHOREA; HYPERSALIVATION; HYPOPHONIA; LUNG FIBROSIS; MOTOR DYSFUNCTION; MYOCLONUS; OROMANDIBULAR DYSTONIA; PARKINSON DISEASE; PLEUROPULMONARY FIBROSIS; POSITIVE END EXPIRATORY PRESSURE; PRIORITY JOURNAL; QUALITY OF LIFE; RESPIRATORY FLUTTER; RESPIRATORY TRACT DISEASE; REVIEW; SHY DRAGER SYNDROME; SLEEP APNEA SYNDROME; SPASMODIC DYSPHONIA; STRIDOR; TARDIVE DYSKINESIA; TIC; UPPER RESPIRATORY TRACT OBSTRUCTION; WITHDRAWAL SYNDROME;

ANTIPARKINSON AGENTS; DYSTONIA; HUMANS; HUNTINGTON DISEASE; HYPERKINESIS; MOVEMENT DISORDERS; MULTIPLE SYSTEM ATROPHY; MYOCLONUS; NERVOUS SYSTEM DISEASES; PARKINSON DISEASE; PNEUMONIA, ASPIRATION; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RESPIRATORY TRACT DISEASES; TICS; TOURETTE SYNDROME;

EID: 78649720302     PISSN: 13538020     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.parkreldis.2010.07.004     Document Type: Review

References (164)

1. Fahn S., Jankovic J. Principles and practice of movement disorders 2007, Churchill Livingstone, Elsevier, Philadelphia.
2. Jankovic J. Treatment of hyperkinetic movement disorders. Lancet Neurol 2009, 8(9):844-856.
3. Nogués M.A., Benarroch E. Abnormalities of respiratory control and the respiratory motor unit. Neurologist 2008, 14(5):273-288.
4. Guyton A., Hall J. Pulmonary ventilation. Textbook of medical physiology 2001, 432-442. HIE, Saunders, Philadelphia, PA. 10th ed. A. Guyton, J. Hall (Eds.).
5. Mostile G., Jankovic J. Treatment of dysautonomia associated with Parkinson's disease. Parkinsonism Relat Disord 2009, 15(Suppl. 3):S224-S232.
6. Parkinson J. An essay on the shaking palsy 1817, Sherwood, Nealy and Jones, London.
7. Shill H., Stacy M. Respiratory complications of Parkinson's disease. Semin Respir Crit Care Med 2002, 23(3):261-265.
8. Meyer T. The larynx for neurologists. Neurologist 2009, 15(6):313-318.
9. Hovestadt A., Bogaard J.M., Meerwaldt J.D., van der Meché F.G., Stigt J. Pulmonary function in Parkinson's disease. J Neurol Neurosurg Psychiatr 1989, 52:329-333.
10. Sabaté M., González I., Ruperez F., Rodríguez M. Obstructive and restrictive pulmonary dysfunctions in Parkinson's disease. J Neurol Sci 1996, 138(1-2):114-119.
11. Schwab R.D., England A.C., Peterson E. Akinesia in Parkinson's disease. Neurology 1959, 1:65-72.
12. Ho A.K., Bradshaw J.L., Iansek R. For better or worse: the effect of levodopa on speech in Parkinson's disease. Mov Disord 2008, 23(4):574-580.
13. Fox C.M., Ramig L.O., Ciucci M.R., Sapir S., McFarland D.H., Farley B.G. The science and practice of LSVT/LOUD: neural plasticity-principled approach to treating individuals with Parkinson disease and other neurological disorders. Semin Speech Lang 2006, 27(4):283-299.
14. Hill A.N., Jankovic J., Vuong K.D., Donovan D. Treatment of hypophonia with collagen vocal cord augmentation in patients with parkinsonism. Mov Disord 2003, 18(10):1190-1192.
15. Belafsky P.C., Postma G.N. Vocal fold augmentation with calcium hydroxylapatite. Otolaryngol Head Neck Surg 2004, 131(4):351-354.
16. Vincken W.G., Gauthier S.G., Dollfuss R.E., Hanson R.E., Darauay C.M., Cosio M.G. Involvement of upper-airway muscles in extrapyramidal disorders: a cause of airflow limitation. N Engl J Med 1984, 311(7):438-442.
17. Jankovic J., Tintner R. Dystonia and parkinsonism. Parkinsonism Relat Disord 2001, 8(2):109-121.
18. Kato B., Yamada K., Horiuchi M., Hirayama T., Hasegawa Y. Case of Parkinson's disease presenting with unique dyspneic attacks caused by oromandibular dystonia and sleep apnea syndrome. Rinsho Shinkeigaku 2007, 47(9):577-580.
19. Onoue H., Yukitake M., Kurohara K., Takasima H., Kuroda Y. A case report of Parkinson's disease presenting with recurrent dyspneic attacks due to focal laryngeal dystonia. Rinsho Shinkeigaku 2003, 43(4):192-194.
20. Grill S. Smothering dystonia in a patient with oromandibular dystonia. Mov Disord 2004, 19(11):1374-1375.
21. Tan E.K., Jankovic J. Botulinum toxin A in patients with oromandibular dystonia: long-term follow-up. Neurology 1999, 53(9):2102-2107.
22. Izquierdo-Alonso J.L., Jimenez-Jimenez F.J., Cabrera-Valdivia F., Mansilla-Lesmes M. Airway dysfunction in patients with Parkinson's disease. Lung 1994, 172(1):47-55.
23. Sabaté M., Rodríguez M., Méndez E., Enríquez E., González I. Obstructive and restrictive pulmonary dysfunction increases disability in Parkinson's disease. Arch Phys Med Rehabil 1996, 77:29-34.
24. Nugent C.A., Harris H.W., Cohn J., Smith C.C., Tyler F.H. Dyspnea as a symptom in Parkinson's syndrome. Am Rev Tuberc 1958, 78(5):682-691.
25. Estenne M., Hubert M., De Troyer A. Respiratory-muscle involvement in Parkinson's disease. N Engl J Med 1984, 311(23):1516-1517.
26. Solomon N.P., Hixon T.J. Speech breathing in Parkinson's disease. J Speech Hear Res 1993, 36(2):294-310.
27. Azher S.N., Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology 2005, 65(3):355-359.
28. Ashour R., Jankovic J. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord 2006, 21(11):1856-1863.
29. Gdynia H.J., Sperfeld A.D., Unrath A., Ludolph A.C., Sabolek M., Storch A., et al. Histopathological analysis of skeletal muscle in patients with Parkinson's disease and 'dropped head'/'bent spine' syndrome. Parkinsonism Relat Disord 2009, 15(9):633-639.
30. Jankovic J. Camptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of parkinsonian deformities. Mov Disord 2010, 25:527-528.
31. Sathyaprabha T.N., Kapavarapu P.K., Pall P.K., Thennarasu K., Raju T.R. Pulmonary functions in Parkinson's disease. Indian J Chest Dis Allied Sci 2005, 47(4):251-257.
32. Saleem A.F., Sapienza C.M., Okun M.S. Respiratory muscle strength training: treatment and response duration in a patient with early idiopathic Parkinson's disease. NeuroRehabilitation 2005, 20(4):323-333.
33. Stanley R.K., Protas E.J., Jankovic J. Exercise performance in those having Parkinson's disease and healthy normals. Med Sci Sports Exerc 1999, 31(6):761-766.
34. Inzelberg R., Peleg N., Nisipeanu P., Magadle R., Carasso R.L., Weiner P. Inspiratory muscle training and the perception of dyspnea in Parkinson's disease. Can J Neurol Sci 2005, 32(2):213-217.
35. Glass G.A., Ku S., Ostrem J.L., Heath S., Larson P.S. Fluoroscopic, EMG-guided injection of botulinum toxin into the longus colli for the treatment of anterocollis. Parkinsonism Relat Disord 2009, 15(8):610-613.
36. Jankovic J. Disease-oriented approach to botulinum toxin use. Toxicon 2009, 54(5):614-823.
37. Sako W., Nishio M., Maruo T., Shimazu H., Matsuzaki K., Tamura T., et al. Subthalamic nucleus deep brain stimulation for camptocormia associated with Parkinson's disease. Mov Disord 2009, 24(7):1076-1079.
38. Sakas D.E., Panourias I.G., Stavrinou L.C., Boviatsis E.J., Themistocleous M., Stathis P., et al. Restoration of erect posture in idiopathic camptocormia by electrical stimulation of the globus pallidus internus. J Neurosurg 2010 Apr 9, [Epub ahead of print].
39. Jankovic J., Nour F. Respiratory dyskinesia in Parkinson's disease. Neurology 1986, 36(2):303-304.
40. Kruk J., Sachdev P., Singh S. Neuroleptic-induced respiratory dyskinesia. J Neuropsychiatry Clin Neurosci 1995, 7(2):223-229.
41. Hartman D.E. Stridor during dystonia phases of Parkinson's disease. J Neurol Neurosurg Psychiatr 1988, 51(1):161.
42. Vazquez A., Jimenez-Jimenez F.J., Garcia-Ruiz P., Garcia-Urra D. "Panic attacks" in Parkinson's disease: a long-term complication of levodopa therapy. Acta Neurol Scand 1993, 87(1):14-18.
43. Rice J.E., Antic R., Thompson P.D. Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease. Mov Disord 2002, 17(3):524-527.
44. Iturriaga R., Alcayaga J., Gonzalez C. Neurotransmitters in carotid body function: the case of dopamine - invited article. Adv Exp Med Biol 2009, 648:137-143.
45. Serebrovskaya T., Karaban I., Mankovskaya I., Bernardi L., Passino C., Appenzeller O. Hypoxic ventilatory responses and gas exchange in patients with Parkinson's disease. Respiration 1998, 65(1):28-33.
46. Jankovic J., Aguilar L.G. Current approaches to the treatment of Parkinson's disease. Neuropsychiatr Dis Treat 2008, 4:743-757.
47. Tintner R., Manian P., Gauthier P., Jankovic J. Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson disease. Arch Neurol 2005, 62(8):1290-1295.
48. Hofmann C., Penner U., Dorow R., Pertz H.H., Jähnichen S., Horowski R., et al. Lisuride, a dopamine receptor agonist with 5-HT2B receptor antagonist properties: absence of cardiac valvulopathy adverse drug reaction reports supports the concept of a crucial role for 5-HT2B receptor agonism in cardiac valvular fibrosis. Clin Neuropharmacol 2006, 29(2):80-86.
49. Antonini A., Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol 2007, 6(9):826-829.
50. Smith S.A., Waggoner A.D., de las Fuentes L., Davila-Roman V.G. Role of serotoninergic pathways in drug-induced valvular heart disease and diagnostic features by echocardiography. J Am Soc Echocardiogr 2009, 22(8):883-889.
51. Easdown L.J., Tessler M.J., Minuk J. Upper airway involvement in Parkinson's disease resulting in postoperative respiratory failure. Can J Anaesth 1995, 42(4):344-347.
52. Harada T., Mitsuoka K., Kumagai R., Murata Y., Kaseda Y., Kamei H., et al. Clinical features of malignant syndrome in Parkinson's disease and related neurological disorders. Parkinsonism Relat Disord 2003, 9(Suppl. 1):15-23.
53. Galvez-Jimenez N., Lang A.E. Perioperative problems in Parkinson's disease and their management: apomorphine with rectal domperidone. Can J Neurol Sci 1996, 23(3):198-203.
54. Nóbrega A.C., Rodrigues B., Melo A. Is silent aspiration a risk factor for respiratory infection in Parkinson's disease patients?. Parkinsonism Relat Disord 2008, 14(8):646-648.
55. Regan J., Walshe M., Tobin W.O. Immediate effects of thermal-tactile stimulation on timing of swallow in idiopathic Parkinson's disease. Dysphagia 2009, [Epub ahead of print].
56. Chou K.L., Evatt M., Hinson V., Kompoliti K. Sialorrhea in Parkinson's disease: a review. Mov Disord 2007, 22(16):2306-2313.
57. Gross R.D., Atwood C.W., Ross S.B., Eichhorn K.A., Olszewski J.W., Doyle P.J. The coordination of breathing and swallowing in Parkinson's disease. Dysphagia 2008, 23(2):136-145.
58. Ebihara S., Saito H., Kanda A., Nakajoh M., Takahashi H., Arai H., et al. Impaired efficacy of cough in patients with Parkinson disease. Chest 2003, 124(3):1009-1015.
59. Menezes C., Melo A. Does levodopa improve swallowing dysfunction in Parkinson's disease patients?. J Clin Pharm Ther 2009, 34(6):673-676.
60. South A.R., Somers S.M., Jog M.S. Gum chewing improves swallow frequency and latency in Parkinson patients: a preliminary study. Neurology 2010, 74(15):1198-1202.
61. Logemann J.A., Gensler G., Robbins J., Lindblad A.S., Brandt D., Hind J.A., et al. A randomized study of three interventions for aspiration of thin liquids in patients with dementia or Parkinson's disease. J Speech Lang Hear Res 2008, 51(1):173-183.
62. Pitts T., Bolser D., Rosenbek J., Troche M., Okun M.S., Sapienza C. Impact of expiratory muscle strength training on voluntary cough and swallow function in Parkinson disease. Chest 2009, 135(5):1301-1308.
63. Stefanova N., Bücke P., Duerr S., Wenning G.K. Multiple system atrophy: an update. Lancet Neurol 2009, 8(12):1172-1178.
64. Köllensperger M., Geser F., Seppi K., Stampfer-Kountchev M., Sawires M., Scherfler C., et al. Red flags for multiple system atrophy. Mov Disord 2008, 23(8):1093-1099.
65. Benarroch E.E., Schmeichel A.M., Low P.A., Parisi J.E. Depletion of putative chemosensitive respiratory neurons in the ventral medullary surface in multiple system atrophy. Brain 2007, 130(2):469-475.
66. Vetrugno R., Provini F., Cortelli P., Plazzi G., Lotti E.M., Pierangeli G., et al. Sleep disorders in multiple system atrophy: a correlative video-polysomnographic study. Sleep Med 2004, 5:21-30.
67. Iranzo A., Santamaria J., Tolosa E. Continuous positive air pressure eliminates nocturnal stridor in multiple system atrophy. Lancet 2000, 356:1329-1330.
68. Ghorayeb I., Yekhlef F., Chrysostome V., Balestre E., Bioulac B., Tison F. Sleep disorders and their determinants in multiple system atrophy. J Neurol Neurosurg Psychiatr 2002, 72(6):798-800.
69. Yamaguchi M., Arai K., Asahina M., Hattori T. Laryngeal stridor in multiple system atrophy. Eur Neurol 2003, 49(3):154-159.
70. Ghorayeb I., Bioulac B., Tison F. Sleep disorders in multiple system atrophy. J Neural Transm 2005, 112(12):1669-1675.
71. Silber M.H., Levine S. Stridor and death in multiple system atrophy. Mov Disord 2000, 15(4):699-704.
72. Isozaki E., Naito A., Horiguchi S., Kawamura R., Hayashida T., Tanabe H. Early diagnosis and stage classification of vocal cord abductor paralysis in patients with multiple system atrophy. J Neurol Neurosurg Psychiatr 1996, 60(4):399-402.
73. Sadaoka T., Kakitsuba N., Fujiwara Y., Kanai R., Takahashi H. Sleep-related breathing disorders in patients with multiple system atrophy and vocal fold palsy. Sleep 1996, 19(6):479-480.
74. Kim H.J., Jeon B.S. Acute respiratory failure due to vocal cord paralysis in a patient with Parkinson's disease. Mov Disord 2009, 24(12):1862-1863.
75. Bannister R., Gibson W., Michaels L., Oppenheimer D.R. Laryngeal abductor paralysis in multiple system atrophy. A report on three necropsied cases, with observations on the laryngeal muscles and the nuclei ambigui. Brain 1981, 104(2):351-368.
76. Merlo I.M., Occhini A., Pacchetti C., Alfonsi E. Not paralysis, but dystonia causes stridor in multiple system atrophy. Neurology 2002, 58(4):649-652.
77. Asahina M., Yamaguchi M., Fukutake T., Hattori T. Sleep apnea in multiple system atrophy. Nippon Rinsho 2000, 58(8):1722-1727.
78. Shiba K., Isono S., Nakazawa K. Paradoxical vocal cord motion: a review focused on multiple system atrophy. Auris Nasus Larynx 2007, 34(4):443-452.
79. Altman K.W., Simpson C.B., Amin M.R., Abaza M., Balkissoon R., Casiano R.R. Cough and paradoxical vocal fold motion. Otolaryngol Head Neck Surg 2002, 127(6):501-511.
80. Sekita Y., Shiba K., Nakazawa K., Numasawa T., Isono S. Inspiratory activation of the vocal cord adductor. Part II: animal study in the cat. Laryngoscope 2004, 114(2):376-380.
81. Shiba K., Isono S., Sekita Y., Tanaka A. Inspiratory activation of the vocal cord adductor. Part I: human study in patients with restricted abduction of the vocal cords. Laryngoscope 2004, 114(2):372-375.
82. Iranzo A., Santamaria J., Tolosa E., Vilaseca I., Valldeoriola F., Martí M.J., et al. Long-term effect of CPAP in the treatment of nocturnal stridor in multiple system atrophy. Neurology 2004, 63(5):930-932.
83. Sant'Ambrogio F.B., Mathew O.P., Clark W.D., Sant'Ambrogio G. Laryngeal influences on breathing pattern and posterior cricoarytenoid muscle activity. J Appl Physiol 1985, 58(4):1298-1304.
84. Ramirez J., Leon I., Rivera L.M. Episodic laryngeal dyskinesia. Clinical and psychiatric characterization. Chest 1986, 90(5):716-721.
85. Ghorayeb I., Yekhlef F., Bioulac B., Tison F. Continuous positive airway pressure for sleep-related breathing disorders in multiple system atrophy: long-term acceptance. Sleep Med 2005, 6(4):359-362.
86. Kuźniar T.J., Morgenthaler T.I., Prakash U.B., Pallanch J.F., Silber M.H., Tippmann-Peikert M. Effects of continuous positive airway pressure on stridor in multiple system atrophy-sleep laryngoscopy. J Clin Sleep Med 2009, 5(1):65-67.
87. Nonaka M., Imai T., Shintani T., Kawamata M., Chiba S., Matsumoto H. Non-invasive positive pressure ventilation for laryngeal contraction disorder during sleep in multiple system atrophy. J Neurol Sci 2006, 247(1):53-58.
88. Jin K., Okabe S., Chida K., Abe N., Kimpara T., Ohnuma A., et al. Tracheostomy can fatally exacerbate sleep-disordered breathing in multiple system atrophy. Neurology 2007, 68(19):1618-1621.
89. Marion M.H., Klap P., Perrin A., Cohen M. Stridor and focal laryngeal dystonia. Lancet 1992, 339(8796):457-458.
90. Kenyon G., Apps M., Traub M. Stridor and obstructive sleep apnea in Shy-Drager syndrome treated by laryngofissure and cord lateralization. Laryngoscope 1984, 94(8):1106-1108.
91. Umeno H., Ueda Y., Mori K., Chijiwa K., Nakashima T., Kotby N. Management of impaired vocal fold movement during sleep in a patient with Shy-Drager syndrome. Am J Otolaryngol 2000, 21(5):344-378.
92. Apps M.C., Sheaff P.C., Ingram D.A., Kennard C., Empey D.W. Respiration and sleep in Parkinson's disease. J Neurol Neurosurg Psychiatr 1985, 48(12):1240-1245.
93. Steffen A., Hagenah J., Graefe H., Mahlerwein M., Wollenberg B. Obstructive sleep apnea in patients with Parkinson's disease - report of two cases and review. Laryngorhinootologie 2008, 87(2):107-111.
94. Ellen R.L., Marshall S.C., Palayew M., Molnar F.J., Wilson K.G., Man-Son-Hing M. Systematic review of motor vehicle crash risk in persons with sleep apnea. J Clin Sleep Med 2006, 2(2):193-200.
95. Gilman S., Chervin R.D., Koeppe R.A., Consens F.B., Little R., An H., et al. Obstructive sleep apnea is related to a thalamic cholinergic deficit in MSA. Neurology 2003, 61(1):35-39.
96. McDaid C., Durée K.H., Griffin S.C., Weatherly H.L., Stradling J.R., Davies R.J., et al. A systematic review of continuous positive airway pressure for obstructive sleep apnoea-hypopnoea syndrome. Sleep Med Rev 2009, 13(6):427-436.
97. Holty J.E., Guilleminault C. Surgical options for the treatment of obstructive sleep apnea. Med Clin North Am 2010, 94(3):479-515.
98. Mejia N., Jankovic J. Tardive dyskinesia and withdrawal emergent in children. Expert Rev Neurother 2010, 10:893-901.
99. Colice G.L., Bernat J.L. Neurologic disorders and respiration. Clin Chest Med 1989, 10:521-543.
100. Chiu H.F., Lam L.C., Chan C.H., Ho C.K., Shum P.P. Clinical and polygraphic characteristics of patients with respiratory dyskinesia. Br J Psychiatry 1993, 162(6):828-830.
101. Komatsu S., Kirino E., Inoue Y., Arai H. Risperidone withdrawal-related respiratory dyskinesia: a case diagnosed by spirography and fibroscopy. Clin Neuropharmacol 2005, 28(2):90-93.
102. Rich M.W., Radwany S.M. Respiratory dyskinesia. An underrecognized phenomenon. Chest 1994, 105(6):1826-1832.
103. Inada T., Yagi G., Kaijima K., Ohnishi K., Kamisada M., Rockhold R.W. Clinical variants of tardive dyskinesia in Japan. Jpn J Psychiatry Neurol 1991, 45(1):67-71.
104. Jackson I.V., Volavka J., James B., Reker D. The respiratory components of tardive dyskinesia. Biol Psychiatry 1980, 15(3):485-487.
105. Werner W.J., Goetz C.C., Nausieda P.A., Klawans H.L. Respiratory dyskinesia: extrapyramidal dysfunction and dyspnea. Ann Intern Med 1978, 88(3):327-331.
106. Guyton A., Hall J. Regulation of acid-base balance. Textbook of medical physiology 2001, 346-362. HIE, Saunders, Philadelphia, PA. 10th ed. A. Guyton, J. Hall (Eds.).
107. Chiu H.F., Lee S., Chan C.H. Misdiagnosis of respiratory dyskinesia. Acta Psychiatr Scand 1991, 83(6):494-495.
108. Thomas M., Jankovic J. Psychogenic movement disorders: diagnosis and management. CNS Drugs 2004, 18(7):437-452.
109. Pasricha P.J., Pehlivanov N., Sugumar A., Jankovic J. Drug Insight: from disturbed motility to disordered movement-a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006, 3(3):138-148.
110. Kenney C., Hunter C., Davidson A., Jankovic J. Metoclopramide, an increasingly recognized cause of tardive dyskinesia. J Clin Pharmacol 2008, 48(3):379-384.
111. Ondo W.G., Hanna P., Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999, 156(8):1279-1281.
112. Kenney C., Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 2006, 6(1):7-17.
113. Krause E., Gürkov R. Local botulinum neurotoxin A therapy in tardive lingual dyskinesia. Laryngorhinootologie 2009, 88(8):508-510.
114. Tschopp L., Salazar Z., Micheli F. Botulinum toxin in painful tardive dyskinesia. Clin Neuropharmacol 2009, 32(3):165-166.
115. Sako W., Goto S., Shimazu H., Murase N., Matsuzaki K., Tamura T., et al. Bilateral deep brain stimulation of the globus pallidus internus in tardive dystonia. Mov Disord 2008 Oct 15, 23(13):1929-1931.
116. Kefalopoulou Z., Paschali A., Markaki E., Vassilakos P., Ellul J., Constantoyannis C. A double-blind study on a patient with tardive dyskinesia treated with pallidal deep brain stimulation. Acta Neurol Scand 2009, 119(4):269-273.
117. Sun B., Chen S., Zhan S., Le W., Krahl S.E. Subthalamic nucleus stimulation for primary dystonia and tardive dystonia. Acta Neurochir Suppl 2007, 97(Pt 2):207-214.
118. Tarsy D., Simon D.K. Dystonia. N Engl J Med 2006, 355(8):818-827.
119. Breakfield X.O., Blood A., Li Y., Hallett M., Hanson P.I., Standaert D.G. The pathophysiological basis of dystonias. Nat Rev Neurosci 2008, 9(3):222-234.
120. Blitzer A., Brin M.F. Laryngeal dystonia: a series with botulinum toxin therapy. Mov Disord 2007, 22(5):673-678.
121. Gallivan G.J., Hoffman L., Gallivan K.H. Episodic paroxysmal laryngospasm: voice and pulmonary function assessment and management. J Voice 1996, 10(1):93-105.
122. Braun N., Abd A., Baer J., Blitzer A., Stewart C., Brin M. Dyspnea in dystonia. A functional evaluation. Chest 1995, 107(5):1309-1316.
123. Tanabe L.M., Kim C.E., Alagem N., Dauer W.T. Primary dystonia: molecules and mechanisms. Nat Rev Neurol 2009, 5(11):598-609.
124. Jankovic J. Treatment of dystonia. Lancet Neurol 2006, 5(10):864-872.
125. Mariotti P., Fasano A., Contarino M.F., Della Marca G., Piastra M., Genovese O., et al. Management of status dystonicus: our experience and review of the literature. Mov Disord 2007, 22:963-968.
126. Lam K.S., Bodfish J.W., Piven J. Evidence for three subtypes of repetitive behavior in autism that differ in familiality and association with other symptoms. J Child Psychol Psychiatry 2008, 49(11):1193-1200.
127. Jankovic J., Jimenez-Shahed J., Brown L.W. A randomized, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. Mov Disord 2009, 24(Suppl. 1):S497.
128. Jankovic J. Tourette's syndrome. N Engl J Med 2001, 345(16):1184-1192.
129. Kim H., Moote W., Mazza J. Tourette's syndrome in patients referred for allergy evaluation. Ann Allergy Asthma Immunol 1997, 79(4):347-349.
130. Tan H., Büyükavci M., Arik A. Tourette's syndrome manifests as chronic persistent cough. Yonsei Med J 2004, 45(1):145-149.
131. Adam O.R., Ferrara J.M., Jankovic J. Motor-phonic tic mimicking essential palatal myoclonus. Mov Disord 2009, 24(13):2030-2032.
132. Sverd J., Montero G. Is Tourette syndrome a cause of sudden infant death syndrome and childhood obstructive sleep apnea?. Am J Med Genet 1993, 46(5):494-496.
133. Berardelli A., Currà A., Fabbrini G., Gilio F., Manfredi M. Pathophysiology of tics and Tourette syndrome. J Neurol 2003, 250(7):781-787.
134. Leckman J.F., Bloch M.H., Scahill L., King R.A. Tourette syndrome: the self under siege. J Child Neurol 2006, 21(8):642-649.
135. Dion Y., Annable L., Sandor P., Chouinard G. Risperidone in the treatment of Tourette syndrome: a double-blind, placebo-controlled trial. J Clin Psychopharmacol 2002, 22(1):31-39.
136. Silay Y., Jankovic J. Emerging drugs in Tourette syndrome. Expert Opin Emerg Drugs 2005, 10(2):365-380.
137. Kenney C., Hunter C., Mejia N., Jankovic J. Tetrabenazine in the treatment of Tourette syndrome. J Pediatr Neurol 2007, 5(1):9-13.
138. Jankovic J., Pardo R. Segmental myoclonus: clinical and pharmacologic study. Arch Neurol 1986, 43:1025-1131.
139. Larner A.J. Antony van Leeuwenhoek and the description of diaphragmatic flutter (respiratory myoclonus). Mov Disord 2005, 20(8):917-918.
140. Hoffman R., Yahr W., Krieger B. Diaphragmatic flutter resulting in failure to wean from mechanical ventilator support after coronary artery bypass surgery. Crit Care Med 1990, 18(5):499-501.
141. Iliceto G., Thompson P.D., Day B.L., Rothwell J.C., Lees A.J., Marsden C.D. Diaphragmatic flutter, the moving umbilicus syndrome, and "belly dancer's" dyskinesia. Mov Disord 1990, 5(1):15-22.
142. Espay A.J., Fox S.H., Marras C., Lang A.E., Chen R. Isolated diaphragmatic tremor: is there a spectrum in "respiratory myoclonus" ?. Neurology 2007, 69(7):689-692.
143. Leeuwenhoek A. De globulorum sanguineorum magnitudine. Philos Trans R Soc Lond 1723, 32:341-343.
144. Phillips J.R., Eldridge F.L. Respiratory myoclonus (Leeuwenhoek's disease). N Engl J Med 1973, 289(26):1390-1395.
145. Rigatto M., de Medeiros N. Diaphragmatic flutter. Report of a case and review of literature. Am J Med 1962, 32:103-109.
146. Cvietusa P.J., Nimmagadda S.R., Wood R., Liu A.H. Diaphragmatic flutter presenting as inspiratory stridor. Chest 1995, 107(3):872-875.
147. Zadikoff C., Lang A.E., Klein C. The "essentials" of essential palatal tremor: a reappraisal of the nosology. Brain 2006, 129(4):832-840.
148. Abdo W.F., van de Warrenburg B.P., Burn D.J., Quinn N.P., Bloem B.R. The clinical approach to movement disorders. Nat Rev Neurol 2010, 6(1):29-37.
149. Cho J.W., Chu K., Jeon B.S. Case of essential palatal tremor: atypical features and remarkable benefit from botulinum toxin injection. Mov Disord 2001, 16(4):779-782.
150. Bollen E.L., Den Heijer J.C., Ponsioen C., Kramer C., Van der Velde E.A., Van Dijk J.G., et al. Respiration during sleep in Huntington's chorea. J Neurol Sci 1988, 84(1):63-68.
151. Hamakawa S., Koda C., Umeno H., Yoshida Y., Nakashima T., Asaoka K., et al. Oropharyngeal dysphagia in a case of Huntington's disease. Auris Nasus Larynx 2004, 31(2):171-176.
152. Banno K., Hobson D.E., Kryger M.H. Long-term treatment of sleep breathing disorder in a patient with Huntington's disease. Parkinsonism Relat Disord 2005, 11(4):261-264.
153. Frank S., Jankovic J. Advances in the pharmacological management of Huntington's disease. Drugs 2010, 70:561-571.
154. Barton B., Zauber E., Goetz C. Movement disorders caused by medical disease. Semin Neurol 2009, 29:97-110.
155. Fasano A., Cadeddu F., Guidubaldi A., Piano C., Soleti F., Zinzi P., et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol 2008, 31(6):313-318.
156. Setter S.M., Neumiller J.J., Dobbins E.K., Wood L., Clark J., DuVall C.A., et al. Treatment of chorea associated with Huntington's disease: focus on tetrabenazine. Consult Pharm 2009, 24(7):524-537.
157. Mestre T., Ferreira J., Coelho M.M., Rosa M., Sampaio C. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009, (3). CD006456.
158. Bonelli R.M., Wenning G.K. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006, 12:2701-2720.
159. Papapetropoulos S., Singer C., McCorquodale D., Gonzalez J., Mash D.C. Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP). Parkinsonism Relat Disord 2005, 11(7):459-463.
160. Yokoji I., Nakamura S., Ikeda T. A case of progressive supranuclear palsy associated with bilateral vocal cord abductor paralysis. Rinsho Shinkeigaku 1997, 37(6):523-525.
161. Panegyres P.K., Hillman D., Dunne J.W. Laryngeal dystonia causing upper airway obstruction in progressive supranuclear palsy. J Clin Neurosci 2007, 14(4):380-381.
162. Yoshimura M. Diffuse Lewy body disease. Rinsho Shinkeigaku 1997, 37(12):1134-1136.
163. Mizukami K., Homma T., Aonuma K., Kinoshita T., Kosaka K., Asada T. Decreased ventilatory response to hypercapnia in dementia with Lewy bodies. Ann Neurol 2009, 65(5):614-617.
164. Tsuda T., Onodera H., Okabe S., Kikuchi Y., Itoyama Y. Impaired chemosensitivity to hypoxia is a marker of multiple system atrophy. Ann Neurol 2002, 52:367-371.